Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. Dialogues Clin Neurosci 13 : — Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
J Am Med Assoc : — Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
J Clin Psychiatry 67 : — Efficacy of atypical v. Br J Psychiatry : — Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry : — Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8 : — Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
CNS Drugs 26 : — J Am Stat Assoc 95 : 89 — Bias in meta-analysis detected by a simple, graphical test. Br Med J : — Emsley RA Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone working group. Schizophr Bull 25 : — Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients.
CNS Spectr 9 : — Typical and atypical antipsychotics—the misleading dichotomy. Neuropsychobiology 57 : 80 — Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry 66 : — ; quiz , — Guy W ECDEU assessment manual for psychopharmacology. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study CUtLASS 1.
Arch Gen Psychiatry 63 : — Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet : — Kane JM Pharmacologic treatment of schizophrenia. Biol Psychiatry 46 : — Past and present progress in the pharmacologic treatment of schizophrenia.
J Clin Psychiatry 71 : — Schizophr Bull 13 : — Arch Gen Psychiatry 64 : — Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 31 : — The schizophrenia patient outcomes research team PORT : updated treatment recommendations Schizophr Bull 30 : — Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet : 31 — Neuropsychopharmacology 32 : — Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a week randomized trial of clozapine vs chlorpromazine.
Neuropsychopharmacology 28 : — Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med : — Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Int J Neuropsychopharmacol 11 : — Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients.
Neuropsychopharmacology 35 : — The brief psychiatric rating scale. Psychol Rep 10 : — Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 64 : 19 — Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Pharmacological treatments for first-episode schizophrenia. Schizophr Bull 31 : — Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study.
J Clin Psychiatry 68 : — Metabolic syndrome in first episode schizophrenia — a randomized double-blind controlled, short-term prospective study. Schizophr Res : — Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry : 79 — Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders TEOSS study.
Hennen J et al. In the light of most recent evidence comparing the relative efficacy of the SGAs, there are no clear-cut differences between them. It is up to the clinician to weigh the risks, the benefits and the cost of each drug and choose the most appropriate therapy for the individual patient. Arch Gen Psychiatry. CNS Drugs. N Engl J Med. Download references.
You can also search for this author in PubMed Google Scholar. Reprints and Permissions. Papageorgiou, G. Comparison of second generation antipsychotics: are there any differences in efficacy?. First versus second generation. What are first and second-generation antipsychotics? What is the evidence for first versus second-generation antipsychotics? Side effects Moderate quality evidence suggests a medium-sized effect of less extrapyramidal side effects with second-generation antipsychotics, particularly olanzapine and risperadone, than with haloperidol.
October Last updated at: am, 15th October To view documentation related to this topic download the files below Fact Sheet Technical Commentary. NeuRA Libraries. Title Colour Legend: Green - Topic summary is available. Bhugra D. The global prevalence of Schizophrenia. PLoS Med ;2 5 :e American Psychiatric Association. Practice guideline for the treatment of patients with Schizophrenia.
Arlington VA. American Psychiatric Association; Carlsson A. Antipsychotic drugs, neurotransmitters, and Schizophrenia. Am J Psychiatry ; 2 Fleischhacker WW. New drugs for the treatment of schizophourenic patients. Acta Psychiatr Scand Suppl ; The use of atypical antipsychotics in the management of Schizophrenia.
Br J Clin Pharmacol ;47 1 Bishara D, Taylor D. Upcoming agents for the treatment of Schizophrenia: mechanism of action, efficacy and tolerability. Drugs ;68 16 Kane J. Commentary: consensus statement on negative symptoms. Schizophour Bull ;32 2 Developing novel antipsychotic drugs: strategies and goals. Schizophour Bull ;25 2 Pharmacological treatment of primary negative symptoms in Schizophrenia: a systematic review. Schizophour Res ;88 Arch Gen Psychiatry ;63 10 Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant Schizophrenia.
Schizophour Bull ;32 4 Effectiveness of antipsychotic drugs in patients with chouronic Schizophrenia. N Engl J Med ; 12 Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chouronic Schizophrenia who did not respond to prior atypical antipsychotic treatment.
Am J Psychiatry ; 4 Lieberman JA. Comparative effectiveness of antipsychotic drugs. Practice guideline for the treatment of patients with bipolar disorder revision. Am J Psychiatry ; 4 Suppl Definition of Terms Not applicable.
Summary of Protocol Amendments In the event of protocol amendments, the date of each amendment will be accompanied by a description of the change and the rationale. In addition, for Comparative Effectiveness reviews, the key questions were posted for public comment and finalized by the EPC after review of the comments. Key Informants Key Informants are the end users of research, including patients and caregivers, practicing clinicians, relevant professional and consumer organizations, purchasers of health care, and others with experience in making health care decisions.
Within the EPC program, the Key Informant role is to provide input into identifying the Key Questions for research that will inform healthcare decisions. The EPC solicits input from Key Informants when developing questions for systematic review or when identifying high priority research gaps and needed new research.
Key Informants are not involved in analyzing the evidence or writing the report and have not reviewed the report, except as given the opportunity to do so thourough the peer or public review mechanism. Because of their role as end-users, individuals are invited to serve as Key Informants and those who present with potential conflicts may be retained.
Technical Experts Technical Experts comprise a multi-disciplinary group of clinical, content, and methodologic experts who provide input in defining populations, interventions, comparisons, or outcomes as well as identifying particular studies or databases to search. They are selected to provide broad expertise and perspectives specific to the topic under development.
Divergent and conflicted opinions are common and perceived as health scientific discourse that results in a thoughtful, relevant systematic review. Technical Experts provide information to the EPC to identify literature search strategies and recommend approaches to specific issues as requested by the EPC.
Because of their unique clinical or content expertise, individuals are invited to serve as Technical Experts and those who present with potential conflicts may be retained. Peer Reviewers Peer reviewers are invited to provide written comments on the draft report based on their clinical, content, or methodologic expertise.
Peer review comments on the preliminary draft of the report are considered by the EPC in preparation of the final draft of the report. Peer reviewers do not participate in writing or editing of the final report or other products. The synthesis of the scientific literature presented in the final report does not necessarily represent the views of individual reviewers.
The dispositions of the peer review comments are documented and will, for CERs and Technical briefs, be published thouree months after the publication of the Evidence report. Peer reviewers who disclose potential business or professional conflicts of interest may submit comments on draft reports thourough the public comment mechanism.
Research Protocol Archived. Systematic Review Archived. Treatment for Adults With Schizophrenia. Page last reviewed December Back to Top.
0コメント